Evidence map›Paper›PMID 26797050›Full record

ReviewMolecular oncology2016

Excellent translational research in oncology: A journey towards novel and more effective anti-cancer therapies.

A Rajan, A Berns, U Ringborg, J Celis, B Ponder, C Caldas, D Livingston, R G Bristow, T T Hecht, T Tursz and 8 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecular oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

A RajanThe Netherlands Cancer Institute, The Netherlands.
A BernsThe Netherlands Cancer Institute, The Netherlands.
U RingborgKarolinska Institutet, Sweden.
J CelisDanish Cancer Society, Denmark.
B PonderCambridge Cancer Centre, UK.
C CaldasCambridge Cancer Centre, UK.
D LivingstonDana-Farber/Harvard Cancer Center, USA.
R G BristowPrincess Margaret Cancer Center, Canada.
T T HechtTranslational Research Program, National Cancer Institute, USA.
T TurszInstitut Gustave Roussy, France.
H van LuenenThe Netherlands Cancer Institute, The Netherlands.
P BonoHelsinki University Central Hospital Cancer Center, Finland.
T HelanderHelsinki University Central Hospital Cancer Center, Finland.
K SeamonCambridge Cancer Centre, UK.
J F SmythUniversity of Edinburgh, UK.
D LouvardInstitut Curie, France.
A EggermontInstitut Gustave Roussy, France.
W H van HartenThe Netherlands Cancer Institute, The Netherlands. Electronic address: w.v.harten@nki.nl.

Funding

Cancer Research UK 16465Cancer Research UK 16942Cancer Research UK 9675Medical Research Council MR/M008975/1
6 · The paper itself

Abstract

Comprehensive Cancer Centres (CCCs) serve as critical drivers for improving cancer survival. In Europe, we have developed an Excellence Designation System (EDS) consisting of criteria to assess "excellence" of CCCs in translational research (bench to bedside and back), with the expectation that many European CCCs will aspire to this status.

Indexed as

Cancer Care FacilitiesQuality of Health CareTranslational Research, BiomedicalEuropeHumansNeoplasmsExcellencePerformance assessmentQuality improvementTranslational research

Identifiers

PMID26797050
PMCPMC5423159

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.